HealthDay - WEDNESDAY, May 11 (HealthDay News) -- A four-drug chemotherapy regimen for deadly pancreatic cancer nearly doubled patients' survival time compared to standard chemotherapy, a new study suggests.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.